Key Decisions and Approvals

The Board of Directors at their meeting held on November 3, 2026 (commenced at 12:15 p.m., concluded at 2:15 p.m.) approved the following:

1. The Unaudited Financial Results of the company for the quarter/half year ended September 30, 2026.

2. The appointment of Ms. Vandana Sinha as Non-Executive Non-Independent Director (Representing LIC of India) of the Company, effective November 3, 2026, subject to approval of the shareholders.

Financial Results Summary (Standalone)

Quarterly Performance (Q2 FY27 vs Q2 FY26)

  • Total Income: ₹8,138.79 lakh (Q2 FY27) vs ₹6,648.53 lakh (Q2 FY26)
  • Profit Before Tax (PBT): ₹4,834.11 lakh (Q2 FY27) vs ₹3,656.53 lakh (Q2 FY26)
  • Tax Expense: ₹975.00 lakh (Q2 FY27) vs ₹750.00 lakh (Q2 FY26)
  • Net Profit from Continuing Operations: ₹3,859.11 lakh (Q2 FY27) vs ₹2,906.53 lakh (Q2 FY26)
  • Total Comprehensive Income for the period: ₹4,377.94 lakh (Q2 FY27) vs ₹3,248.00 lakh (Q2 FY26)

Half-Yearly Performance (H1 FY27 vs H1 FY26)

  • Total Income: ₹19,654.00 lakh (H1 FY27) vs ₹13,230.40 lakh (H1 FY26)
  • Profit Before Tax (PBT): ₹12,666.13 lakh (H1 FY27) vs ₹7,472.42 lakh (H1 FY26)
  • Tax Expense: ₹2,686.09 lakh (H1 FY27) vs ₹1,510.00 lakh (H1 FY26)
  • Net Profit from Continuing Operations: ₹9,980.04 lakh (H1 FY27) vs ₹5,962.42 lakh (H1 FY26)
  • Total Comprehensive Income for the period: ₹10,484.10 lakh (H1 FY27) vs ₹6,281.97 lakh (H1 FY26)

Key Income Statement Line Items (Q2 FY27)

  • Interest Income: ₹8,018.36 lakh
  • Dividend Income: ₹6,422.77 lakh
  • Fee & Commission Income: ₹360.35 lakh
  • Income from Net Gain/(Loss) on fair value changes: ₹622.42 lakh
  • Other Income: ₹120.43 lakh

Key Expense Line Items (Q2 FY27)

  • Finance Costs: ₹2,595.68 lakh
  • Employee Benefits Expense: ₹397.35 lakh
  • Depreciation and Amortization Expense: ₹14.04 lakh
  • Other Operating Expenses: ₹297.61 lakh

Asset and Liability Position (as of September 30, 2026)

  • Total Assets: ₹2,57,447.94 lakh
  • Financial Assets: ₹2,55,695.15 lakh
  • Investments: ₹2,07,410.09 lakh
  • Bank balances: ₹4,846.32 lakh
  • Loans & Advances: ₹73.38 lakh
  • Other financial assets: ₹41,498.94 lakh
  • Non-Financial Assets: ₹1,752.79 lakh
  • Total Liabilities and Equity: ₹2,57,447.94 lakh
  • Financial Liabilities: ₹1,18,000.31 lakh
  • Debt Securities: ₹17,474.24 lakh
  • Borrowings (Other than Debt Securities): ₹97,672.23 lakh
  • Equity: ₹1,39,187.33 lakh
  • Equity Share Capital: ₹9,259.54 lakh
  • Other Equity: ₹1,29,927.79 lakh

Key Financial Ratios (as of September 30, 2026)

  • Net Profit Margin (%): 44.97%
  • Gross NPA (%): 0.37%
  • Net NPA (%): Nil
  • Provision Coverage Ratio (%): 400.00%
  • Capital Risk Adequacy Ratio (CRAR) (%): 54.68%
  • Total Debt to Equity Ratio: 3.00%

Management Change Details

  • Appointee: Ms. Vandana Sinha
  • Role: Non-Executive Non-Independent Director (Representing LIC of India)
  • Effective Date: November 3, 2026
  • Approval Status: Subject to shareholder approval
  • DIN: 12032857
  • Background: Ms. Sinha has over 36 years of experience in the life insurance industry, currently serving as Executive Director (Sales) at LIC of India. She is not related to any other director or key managerial personnel of the company.

Regulatory and Compliance Information

  • The results were reviewed by the Audit Committee and approved by the Board.
  • The limited review was conducted by Rama K. Gupta & Co., Chartered Accountants (FRN 005005C), who issued an unmodified report.
  • The financial results are prepared in accordance with Ind AS 34 and comply with Regulation 33 and 52 of SEBI (LODR) Regulations, 2015.
  • The company received income tax refunds amounting to ₹808.35 lakh (including interest) for AYs 1995-96 to 2002-03 during Q1 FY27, which was recognized as other income.
  • Provision for Expected Credit Loss (ECL) on loan assets has been made as per Ind AS 109. The provision made is higher than RBI IRACP requirements.
  • The company is primarily engaged in financing and investment business, with no separate reportable segments.